Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Analysis

Non-alcoholic Steatohepatitis Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2026

Category: Healthcare Report Format : PDF Report Code: ZMR-6113 Status : Upcoming

Description

Global Non-alcoholic Steatohepatitis Biomarkers Market: Overview

An advanced form of non-alcoholic fatty liver disease (NAFLD) is termed non-alcoholic steatohepatitis (NASH). NASH is liver damage and inflammation caused by a buildup of fats in the liver. In some cases, NASH can be worse and cause scarring of the liver thereby resulting in cirrhosis. The invasive nature of the liver biopsy as a diagnostic procedure has demanded the development of new biomarkers for the diagnosis of NASH.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Global Non-alcoholic Steatohepatitis Biomarkers Market: Growth Factors

The global non-alcoholic steatohepatitis biomarkers market is growing at a faster pace. Factors such as the growing prevalence of non-alcoholic steatohepatitis (NASH) worldwide, the increase in the necessity of early & appropriate diagnosis of NASH, and the increase in healthcare expenditure are augmenting the growth of the global market. NASH is a progressive form of NAFLD and is strongly related to type 2 diabetes mellitus. In the Western population, NASH is expected to be the most common chronic liver condition. In the United States, the published prevalence projects that around 20 to 30 percent of the population is living with NAFLD and 2 to 5 percent with NASH. By 2030, the prevalence of the NASH is expected to rise by 63 percent. To reduce such a huge clinical burden there is a rise in initiatives undertaken by the government, patient advocacy & support groups, and national public health groups to spread awareness and improve education related to NASH, its diagnosis, and treatment. All such factors coupled with an increase in funds for the research and development as well as for conducting clinical trials to check the efficacy and safety of the biomarkers are fostering the growth of the global non-alcoholic steatohepatitis biomarkers market. Moreover, increase in focus of the key players in the expansion of pipeline products, rise in the number of patients waiting for liver transplantation with the necessity of noninvasive biomarker tests, and a growing number of contract research organizations supporting the development of NASH biomarkers are also the prime factors that are boosting the growth of the global market. Furthermore, technological advancement for the development of different types of biomarkers may build numerous opportunities for the growth of the global non-alcoholic steatohepatitis biomarkers market over the forecast period. However, the high cost associated with the biomarker test may hinder the growth of the global non-alcoholic steatohepatitis biomarkers market in developing and underdeveloped countries.

The key manufacturers working in the non-alcoholic steatohepatitis biomarkers market are facing major challenges as they were enforced to cease their entire developmental unit due to the regulations such as nationwide lockdown and restrictions on movement imposed by the government. In addition to this, clinical trials were also temporarily ceased to maintain the social distancing policies and curb the spread of the disease. The non-emergency healthcare cases were postponed as treatment of Covid-19 patients was on priority. Thus, the Covid-19 pandemic has adversely affected the growth of the global non-alcoholic steatohepatitis biomarkers market.

Global Non-alcoholic Steatohepatitis Biomarkers Market: Segmentation

The global non-alcoholic steatohepatitis biomarkers market is bifurcated into biomarker type, end-user, and region. Based on the biomarker type, the global non-alcoholic steatohepatitis biomarkers market is divided into serum biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and other biomarkers. Based on the end-user, the global market is split into the pharma & CRO industry, academic research institutes, diagnostic labs, and hospitals.

Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Analysis

North America is expected to hold a major share in the global non-alcoholic steatohepatitis biomarkers market during the forecast period. The major share of the market is attributed to the increasing prevalence of chronic liver diseases. Additionally, funding for research activities is more for non-alcoholic steatohepatitis biomarkers, hence supporting the development of a new drug which is ultimately fueling the growth of the market. Asia Pacific is expected to register significant growth over the forecast period. A large number of the targeted patient group, growing research & development activities, and large investments by major players in the market are expected to contribute significant revenue growth over the forecast period.

Global Non-alcoholic Steatohepatitis Biomarkers Market: Competitive Players

The global non-alcoholic steatohepatitis biomarkers market is highly competitive due to the growing necessity of effective diagnostic tools. Some of the prominent players operating in the global non-alcoholic steatohepatitis biomarkers market are GENFIT, Pfizer, Inc., Allergan Novo Nordisk A/S, Novartis AG, Gilead, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, AstraZeneca, Merck & Co, and Quest Diagnostics, among others.

Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

Table Of Content

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global non-alcoholic steatohepatitis biomarkers market is growing at a faster pace. Factors such as the growing prevalence of non-alcoholic steatohepatitis (NASH) worldwide, the increase in the necessity of early & appropriate diagnosis of NASH, and the increase in healthcare expenditure are augmenting the growth of the global market. Furthermore, technological advancement for the development of different types of biomarkers may build numerous opportunities for the growth of the global non-alcoholic steatohepatitis biomarkers market over the forecast period.

The global non-alcoholic steatohepatitis biomarkers market is highly competitive due to the growing necessity of effective diagnostic tools. Some of the prominent players operating in the global non-alcoholic steatohepatitis biomarkers market are GENFIT, Pfizer, Inc., Allergan Novo Nordisk A/S, Novartis AG, Gilead, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, AstraZeneca, Merck & Co, and Quest Diagnostics, among others.

North America is expected to hold a major share in the global non-alcoholic steatohepatitis biomarkers market during the forecast period. The major share of the market is attributed to the increasing prevalence of chronic liver diseases. Additionally, funding for research activities is more for non-alcoholic steatohepatitis biomarkers is more, hence supporting the development of a new drug which ultimately fueling the growth of the market.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed